We've put some small files called cookies on your device to make our site work.
We'd also like to use analytics cookies. These send information about how our site is used to a service called Google Analytics. We use this information to improve our site.
Let us know if this is OK. We'll use a cookie to save your choice. You canĀ read more about our cookies before you choose.
Clinical commissioning policy: Nebulised liposomal amikacin for the treatment of non-tuberculous mycobacterial pulmonary disease caused by mycobacterium avium complex refractory to current treatment options (adults and post pubescent children)
Nebulised liposomal amikacin for the treatment of non-tuberculous mycobacterial pulmonary disease (NTMPD) caused by mycobacterium avium complex (MAC) refractory to current treatment options within the criteria set out in this document.